Maintenance of reduction in disease activity and partial remission in patients with Ankylosing spondylitis (AS) - 3-year results from the adalimumab (HUMIRO) trial evaluating long-term efficacy and safety in AS (ATLAS)
Những tác giả chính: | , , , , , , , , , , |
---|---|
Định dạng: | Conference item |
Được phát hành: |
2008
|